Exelixis Q1 2023 Results: $408.8M Revenues $0.16 Non-GAAP EPS
Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company focused on the development and commercialization of cancer therapies, announced its financial results for the first quarter of 2023. The company reported total…